AI Insight
The American Gastroenterological Association and American Association for the Study of Liver Diseases have released their first joint clinical guideline specifically evaluating newer drug treatments for primary biliary cholangitis, the most prevalent cholestatic liver disease in adults. The guideline, published in both Gastroenterology and HEPATOLOGY journals, provides evidence-based recommendations for both diagnosing and treating this condition using recently developed medications.
Why it matters
This guideline fills a critical gap by formally evaluating newer therapeutic options for PBC patients, potentially improving treatment outcomes for those who do not respond adequately to traditional therapies. The joint endorsement by two major gastroenterology organizations provides clinicians with authoritative, evidence-based guidance for managing this chronic liver condition.
Understand the Science
For the first time, a joint guideline from the American Gastroenterological Association (AGA) and American Association for the Study of Liver Diseases (AASLD) evaluates newer medications for primary biliary cholangitis (PBC), the most common cholestatic disease in adults. Published in Gastroenterology and HEPATOLOGY, the guideline provides evidence-based recommendations for diagnosis and treatment.
Source: First drug-focused guideline outlines newer treatments for primary biliary cholangitis